|
Prof. Friedman has extensive experience in the field of oral drug delivery as well as industrial pharmaceutics. He has published more than 130 papers and holds 24 US patents. He invented the PerioChip, the flagship product of Perio Products, a multimillion-dollar drug delivery company that was eventually sold to a leading pharmaceutical manufacturer. Prof. Friedman is a faculty member at the Hebrew University of Jerusalem School of Pharmacy, and has served as the Academic Head of the School of Pharmacy and Chairman of its Department of Pharmaceutics. Professor Friedman also serves as a consultant for local and international pharmaceutical companies.
|
|
Prof. Hoffman is the Chairman of the Department of Pharmaceutics and founder and Head of the Clinical Pharmacy Program at the Hebrew University of Jerusalem School of Pharmacy. An Associate Professor at The Hebrew University of Jerusalem, he has been teaching there since 1989. He has over 15 years experience in the field of pharmacokinetics and pharmacodynamics, specializing in the biological aspects of drug delivery systems. Prof. Hoffman has published over 70 scientific papers.
|
|
Dr. Fahn is the H. Houston Merritt Professor of Neurology and Director of the Center for Parkinson's Disease and Other Movement Disorders at Columbia University. He is the Scientific Director of the Parkinson's Disease Foundation. Dr. Fahn has twice served as Chairman of the Advisory Committee on Peripheral and Central Nervous System Drugs for the Food and Drug Administration.
|
|
Dr. Hanauer, a recognized expert in inflammatory bowel disease, is Professor of Medicine and Clinical Pharmacology and Chief, Section of Gastroenterology and Nutrition at the University of Chicago. As former Chair of the GI Advisory Panel for the US Food and Drug Administration, Dr. Hanauer authored the FDA's "Guidelines for Clinical Evaluation of Drugs for Patients with Inflammatory Bowel Disease".
|
|
Dr. Lanza is Clinical Professor of Medicine in the Section of Gastroenterology at the Baylor College of Medicine in Houston, Texas. He is also the Director of the Houston Institute for Clinical Research in Houston. His primary research interest is injury to the GI tract from NSAIDs and other agents. He has published over 100 papers on this and other subjects in peer-reviewed journals. He also maintains a small private consultation practice in Gastroenterology.
|
Dr. Roth's research primarily focuses on sleep processes. His work includes research on sleep loss, sleep fragmentation, and deviation from sleep processes including pharmacological effects and sleep pathologies.
Dr. Roth has held numerous leadership positions within his field. His is former chairman of the National Center on Sleep Disorders Research Advisory Board at the National Institutes of Health and former president of the United States Sleep Research Society, the American Sleep Disorders Association, and the National Sleep Foundation. He also served as past editor-in-chief of the journal Sleep. In addition to his position at Henry Ford, he is a clinical professor of Psychiatry at the University of Michigan School of Medicine in Ann Arbor. He has published over 325 manuscripts, 13 edited volumes, 170 chapters, and 491 abstracts.
|
|
Dr. Greenblatt is Professor and Chairman of the Department of Pharmacology and Experimental Therapeutics, and Professor of Psychiatry, Medicine, and Anesthesia, Tufts University School of Medicine. He is Director of the Clinical Pharmacology Program at Tufts University School of Medicine and Tufts Medical Center, and Associate Program Director of the institution’s Clinical Research Center. Dr. Greenblatt has been an active investigator in a number of areas, including: the pharmacokinetics, pharmacodynamics, and neuroreceptor properties of the benzodiazepine derivatives. Dr. Greenblatt is the author of over 700 original research publications.
|
|
Dr. Katz is the chairman of the Division of Gastroenterology and Nutrition at Albert Einstein Medical Center in Philadelphia. He is a recognized authority on esophageal disease whose primary research interests include all aspects of gastro esophageal reflux disease, nocturnal recovery of gastric acid secretion during proton pump inhibitor therapy, and esophageal pain perception.
|
|
Dr. Fleischer is Vice President, Clinical Pharmacology & Biopharmaceutics at The Weinberg Group Inc. He formerly held several senior management positions at the FDA, the most recent being Director of the Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research (CDER).
|
|
